Agenus shared a post on LinkedIn:
“Agenus is pleased to announce the appointment of Jose Iglesias as Chief Medical Affairs Officer, effective November 10, 2025.
Dr. Iglesias brings more than 30 years of global oncology and immuno-oncology experience across biologics, small molecules, and immunotherapies to lead medical strategy for botensilimab + balstilimab (BOTBAL) through Phase 3 and expanding global access programs — including France’s fully reimbursed AAC for microsatellite-stable colorectal cancer, where patient treatment has already begun.
Read full release.”
More posts featuring Agenus.